MST-02

MST-02 is a preclinical-stage therapeutic candidate being developed by Miist Therapeutics for the acute treatment of migraine. The drug utilizes the company's proprietary Miist technology, which formulates active pharmaceutical ingredients into inhaled microparticles designed for deep lung delivery. This approach is intended to provide rapid systemic absorption and a fast onset of action, potentially matching the pharmacokinetic profile of intravenous administration while offering the convenience of a non-invasive inhaler. While the specific active ingredient of MST-02 has not been publicly disclosed, it follows the company's lead program, MST-01 (inhaled sumatriptan), in targeting migraine symptoms.